



## TREATMENT FOR ALCOHOLISM AND RELAPSE INDUCED BY ADDICTION

Biopharmaceutical and therapy based in the non-invasive use of mesenchymal stem cells.

*The excessive consumption of alcohol is one of the main public health problems in the world. According to OMS data, 3.3 millions of deaths annually can be attributed to it, which represents the 5.9% of total deaths, increasing to a 25% in the most vulnerable age group (16 to 39 years old). Current available pharmacological treatments are based in the use of drugs that show little therapeutical effect and very little adherence, being used in fewer than 20% of alcoholism patients.*

### THE TECHNOLOGY

Therapy and biopharmaceutical acellular product derived from preconditioned mesenchymal stem cells (MSCp) for the treatment of alcoholism and alcohol relapse. This treatment, through the reduction of cerebral inflammatory effects, allows the reduction of chronic consumption of alcohol and other drugs (nicotine, cocaine, amphetamines) and to block the relapse induced by their abstinence.

### DEVELOPMENT LEVEL

Proof of concept performed at lab scale. It was proven that the administration of a single dose of MSCp and their derivatives reduced the chronic consumption of alcohol and prevented the relapse when administered to an alcoholic rat model.

### LEAD RESEARCHER

Fernando Ezquer, PhD.

### INTELLECTUAL PROPERTY

Pending patent of shared ownership: UDD (66.5%) and UCHILE (33.5%)

### MAIN BENEFITS AND ADVANTAGES

1. Prolonged effect of weekly administration.
2. Non-invasive administration method.
3. Reduced side-effects.
4. High stability and easy storage.

### APPLICATIONS AND USES

Treatment for alcoholism.  
Treatment for dependency to other addictive drugs.

### TECHNOLOGICAL OFFER

- Partner needed to continue with technological development and validation.
- Technology available for licencing at current development level.

### CONTACT

iCono UDD  
E-mail: [icono@udd.cl](mailto:icono@udd.cl),  
Phone: (56-2) 23279612/225785529